Advances In Immunotherapy-Emerging Treatment Paradigms for Cancer

Abstract

Background: Lung cancer predominantly comprises non-small cell lung cancer (NSCLC), which accounts for a large portion of cancer cases and remains a leading cause of cancer- related mortality worldwide. Traditional chemotherapy provides limited benefit and is associated with significant toxicity, highlighting the need for more effective and targeted treatment such as monoclonal antibodies. Objective: The aim of this study to evaluate the effectiveness, quality of life effects, and adverse event profile of nivolumab, a PD-1 immune checkpoint inhibitor, compared to standard first-line therapy in patients with advanced NSCLC. Methods: A randomized controlled trial includes 60 patients diagnosed with stage III and IV NSCLC. Patient are assigned to receive either nivolumab (240 mg i.v biweekly) (Group A) or platinum-based chemotherapy (Group B). Tumor size, quality of life, and side effects are assessed over a 12- week period using imaging and clinical evaluation. Results: Tumor size reduces by 40% in Group A and 25% in Group B. Quality of life scores for Group A increased from 60 to 70, while Group B values declined from 60 to 52. Group A exhibited fewer and less severe adverse effects than Group B, with no instances of Grade 4 toxicity recorded in Group A, in contrast to two cases of Grade 4 toxicity in Group B. Conclusion: The study's findings indicate that, unlike conventional chemotherapy protocols, nivolumab exhibited more efficacy and safety, favorably affecting tumor response and improving patient's quality of life while minimizing treatment-related side effects. This is a crucial therapeutic alternative for advanced NSCLC.